Table 2.
Respiratory parameters measured during conscious capsaicin challenge in in naive (N = 6), naive + 3 mg/kg CNO (N = 6), control AAV + 3 mg/kg CNO (N = 9), and hM3D(Gq) + 3 mg/kg CNO rats (N = 10) rats
| Capsaicin | Naive (N = 6) | Naive + 3 mg/kg CNO (N = 6) | Control AAV + 3 mg/kg CNO (N = 9) | hM3D (Gq) + 3 mg/kg CNO (N = 10) |
|---|---|---|---|---|
| Respiratory rate (% change from vehicle) | ||||
| 0.3 µM | 6.08 ± 10.23% | 8.07 ± 9.07% | 14.51 ± 14.20% | −11.53 ± 9.76%*,# |
| 3 µM | 6.98 ± 11.12% | 14.19 ± 22.24% | 11.17 ± 10.19% | −12.37 ± 9.24%*,#,^ |
| 30 µM | 14.40 ± 7.71% | 12.76 ± 16.50% | 20.44 ± 12.62% | −7.98 ± 11.67%*,#,^ |
| 100 µM | 23.70 ± 10.85% | 23.57 ± 18.08% | 26.70 ± 12.20% | −1.00 ± 9.88%*,#,^ |
| 300 µM | 20.77 ± 6.89% | 27.11 ± 24.22% | 36.71 ± 11.84% | 11.33 ± 15.42%* |
| Inspiratory time (% change from vehicle) | ||||
| 0.3 µM | −2.30 ± 6.58% | −5.03 ± 6.36% | −7.74 ± 11.38% | 23.73 ± 18.06%*,#,^ |
| 3 µM | −2.84 ± 5.33% | −9.53 ± 11.99% | −5.68 ± 13.75% | 23.91 ± 20.29%*,#,^ |
| 30 µM | −0.56 ± 9.07% | −7.88 ± 12.18% | −16.58 ± 13.12% | 18.38 ± 21.90%*,#,^ |
| 100 µM | −5.46 ± 5.68% | −18.83 ± 9.47% | −19.02 ± 11.44% | 0.83 ± 13.88%*,# |
| 300 µM | −7.38 ± 5.04% | −19.08 ± 13.47% | −21.60 ± 7.93% | −4.32 ± 12.56%* |
| Expiratory time (% change from vehicle) | ||||
| 0.3 µM | −9.63 ± 8.41% | −7.44 ± 13.96% | −12.85 ± 14.82% | 4.11 ± 10.01%* |
| 3 µM | −4.33 ± 15.83% | −7.77 ± 16.72% | −11.23 ± 9.45% | 7.45 ± 11.78%* |
| 30 µM | −10.53 ± 14.83% | −6.87 ± 16.28% | −12.71 ± 11.66% | 6.84 ± 18.25%* |
| 100 µM | −18.47 ± 11.59% | −6.22 ± 17.72% | −14.15 ± 7.23% | 9.76 ± 13.46%*,^ |
| 300 µM | −18.47 ± 8.97% | −8.93 ± 22.32% | −21.29 ± 12.32% | −5.84 ± 9.77% |
| Tidal volume (% change from vehicle) | ||||
| 0.3 µM | −1.61 ± 13.49% | −1.49 ± 12.61% | −9.83 ± 19.51% | −6.32 ± 10.38% |
| 3 µM | 5.41 ± 13.92% | 0.46 ± 15.99% | −12.12 ± 16.03% | −6.81 ± 16.12% |
| 30 µM | 15.79 ± 8.66% | −2.12 ± 11.13% | 3.26 ± 17.72% | 4.39 ± 25.65% |
| 100 µM | 18.54 ± 13.61% | 14.41 ± 20.07% | 10.74 ± 19.65% | 30.80 ± 20.29% |
| 300 µM | 17.99 ± 7.10% | 17.76 ± 12.24% | 22.33 ± 19.39% | 23.83 ± 18.61% |
| Minute volume (% change from vehicle) | ||||
| 0.3 µM | 3.44 ± 21.37% | 5.36 ± 6.81% | 3.48 ± 20.43% | −17.92 ± 9.42% |
| 3 µM | 8.39 ± 20.46% | 10.40 ± 8.75% | −1.67 ± 17.20% | −17.74 ± 15.71%# |
| 30 µM | 29.93 ± 12.36% | 6.16 ± 4.31% | 26.51 ± 27.54% | −7.27 ± 23.04%*,^ |
| 100 µM | 40.43 ± 21.58% | 31.86 ± 10.47% | 39.09 ± 27.88% | 23.75 ± 29.25% |
| 300 µM | 38.78 ± 14.63% | 41.64 ± 22.34% | 60.07 ± 21.87% | 31.71 ± 21.78%* |
| Peak inspiratory flow (% change from vehicle) | ||||
| 0.3 µM | 2.70 ± 19.16% | 2.40 ± 12.18% | −1.44 ± 25.60% | −12.81 ± 20.14% |
| 3 µM | 3.39 ± 13.84% | 13.46 ± 13.50% | −6.05 ± 23.46% | −25.03 ± 23.32%# |
| 30 µM | 17.63 ± 15.97% | 8.40 ± 6.61% | 24.17 ± 31.54% | −12.06 ± 39.49%* |
| 100 µM | 22.67 ± 19.08% | 43.46 ± 15.74% | 33.93 ± 30.83% | 24.71 ± 34.01% |
| 300 µM | 20.13 ± 16.50% | 43.39 ± 21.15% | 46.49 ± 34.27% | 20.20 ± 32.41% |
| Peak expiratory flow (% change from vehicle) | ||||
| 0.3 µM | −3.84 ± 17.87% | 3.21 ± 5.60% | 0.78 ± 9.31% | −9.88 ± 16.44% |
| 3 µM | 16.60 ± 17.97% | 10.92 ± 5.50% | −1.40 ± 10.52% | −7.51 ± 19.49% |
| 30 µM | 28.28 ± 14.15% | 19.42 ± 11.46% | 23.29 ± 20.19% | 12.57 ± 33.11% |
| 100 µM | 31.68 ± 18.61% | 43.04 ± 16.30% | 32.93 ± 20.54% | 38.65 ± 35.94% |
| 300 µM | 24.75 ± 9.16% | 47.51 ± 27.14% | 52.56 ± 15.66% | 40.94 ± 30.21% |
| Penh (% change from vehicle) | ||||
| 0.3 µM | −15.47 ± 17.78% | −1.22 ± 16.82% | 27.87 ± 49.34% | −2.30 ± 14.58% |
| 3 µM | 44.26 ± 39.98% | 2.10 ± 15.09% | 36.30 ± 42.56% | 14.80 ± 19.44% |
| 30 µM | 23.89 ± 35.47% | 36.67 ± 45.69% | 26.60 ± 35.34% | 33.40 ± 36.02% |
| 100 µM | 2.58 ± 23.08% | 29.19 ± 50.81% | 22.57 ± 35.88% | 5.22 ± 34.86% |
| 300 µM | −19.10 ± 21.49% | 7.97 ± 23.01% | 21.18 ± 41.95% | 4.75 ± 22.91% |
Data are represented as the mean ± SD for each group challenged with increasing doses of capsaicin. *,#,^hM3D(Gq) + CNO group significantly different versus control AAV + CNO, naive + CNO, and naive groups, respectively, as determined by Bonferroni's multiple-comparisons test.
*,#,^hM3D(Gq) + CNO group significantly different to Control AAV + CNO group, naive + CNO group, or naive group, respectively as determined by Bonferroni's multiple-comparisons test.